Cohance Lifesciences Limited — Q1FY27 earnings call summary

Filed 05 August 2026 · Company audio recording

Price increases passed on to customers to mitigate RM inflation; margin recovery expected weighted towards H2 FY27.
FY27 filings: 7 new APIs targeted; 10 product launches planned in formulations segment.
Q2 expected to show sequential revenue improvement; year-on-year growth anticipated from H2 FY27.
Oligonucleotide business (Sepala) targeting integrated offering and full ownership by FY30; 2.5x revenue growth in Q1.
Specialty Chemicals skewed to H2 FY27 due to seasonality; aiming for double-digit growth from FY28.
Q1 consolidated gross margin at 71.5% vs 73% YoY; impacted by product mix, lower pharma contribution, and higher freight/RM costs.
Two molecules moved to commercial supply; six intermediates deliveries scheduled in Q2/Q3; restocking order visibility for FY27/FY28.
ADC and oligonucleotide businesses currently cost-heavy; revenue ramp-up critical for margin improvement.